Find High Quailty Sorafenib (284461-73-0) on LEAPChem.com Now!
Nov. 2018/10/11 13:49:17 By LEAP Chem
LEAPChem - Pharmaceutical Chemicals is a premier supplier of pharmaceutical chemicals and other chemical raw materials for global customers including drug manufacturers, universities, research labs, R&D centers, and other industries that use chemical raw materials such as polymers, textiles, agriculture, coatings, etc. As an ISO 9001:2015 certified company, our team of experts in customer service, product sourcing, logistics, regulatory and compliance operate at the highest standard. LEAPChem's experienced sales team will work tirelessly to find the chemicals you need for a price you can afford. By coming to the LEAPChem - Pharmaceutical Chemicals website, you have come one step closer to acquiring your trouble free pharmaceutical chemicals. LEAPChem is happy to highlight Sorafenib.
Basic Information of Sorafenib
Chemical Name: Sorafenib
Cas No.: 284461-73-0
Molecular Formula: C21H16ClF3N4O3
Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.
At the current time sorafenib is indicated as a treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC) and thyroid cancer.
Clinical trial results, published January 2007, showed that, compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear cell renal cell carcinoma in whom previous therapy has failed. The median progression-free survival was 5.5 months in the sorafenib group and 2.8 months in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55; P<0.01).
In Australia this is one of two TGA-labelled indications for sorafenib, although it is not listed on the Pharmaceutical Benefits Scheme for this indication.
At ASCO 2007, results from the SHARP trial were presented, which showed efficacy of sorafenib in hepatocellular carcinoma. The primary endpoint was median overall survival, which showed a 44% improvement in patients who received sorafenib compared to placebo (hazard ratio 0.69; 95% CI, 0.55 to 0.87; p=0.0001). Both median survival and time to progression showed 3-month improvements; however, there was no significant difference in median time to symptomatic progression (p=0.77). There was no difference in quality of life measures, possibly attributable to toxicity of sorafenib or symptoms related to underlying progression of liver disease. Of note, this trial only included patients with Child-Pugh Class A (i.e. mildest) cirrhosis.[ Because of this trial Sorafenib obtained FDA approval for the treatment of advanced hepatocellular carcinoma in November 2007.
In a randomized, double-blind, phase II trial combining sorafenib with doxorubicin, the median time to progression was not significantly delayed compared with doxorubicin alone in patients with advanced hepatocellular carcinoma. Median durations of overall survival and progression-free survival were significantly longer in patients receiving sorafenib plus doxorubicin than in those receiving doxorubicin alone.
A prospective single-centre phase II study which included the patients with unresectable hepatocellular carcinoma (HCC)concluding that the combination of sorafenib and DEB-TACE in patients with unresectable HCC is well tolerated and safe, with most toxicities related to sorafenib.
In Australia this is the only indication for which sorafenib is listed on the PBS and hence the only Government-subsidised indication for sorafenib. Along with renal cell carcinoma, hepatocellular carcinoma is one of the TGA-labelled indications for sorafenib.
On November 22, 2013, sorafenib was approved by the FDA for the treatment of locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment.
The Phase 3 DECISION trial showed significant improvement in progression-free survival but not in overall survival. However, as is known, the side effects were very frequent, specially hand and foot skin reaction.
A phase 3 clinical trial is under way testing the effectiveness of Sorafenib to treat desmoid tumors (also known as aggressive fibromatosis), after positive results in the first two trial stages. Dosage is typically half of that applied for malignant cancers (400 mg vs 800 mg). NCI are sponsoring this trial.
LEAPChem is continually expanding its scope within the pharmaceutical chemicals industry. Our passion for professional development enables us to accommodate our customers’ chemical requirements, and to distribute chemicals with applications that span several classes and functions. All of which allow us to ensure you will receive the same high quality service and chemicals each and every time. LEAPChem is proud to shed awareness on Pterostilbene, a very promising chemical in the dietary supplement market.
If you are interested in Sorafenib, click here to send an inquiry!
Make LEAPChem your pharmaceutical chemicals long-term partner and contact us today!